{"id":892491,"date":"2025-10-06T07:11:11","date_gmt":"2025-10-06T11:11:11","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-highlights-recent-achievements-and-near-term-strategic-priorities\/"},"modified":"2025-10-06T07:11:11","modified_gmt":"2025-10-06T11:11:11","slug":"exicure-highlights-recent-achievements-and-near-term-strategic-priorities","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-highlights-recent-achievements-and-near-term-strategic-priorities\/","title":{"rendered":"Exicure Highlights Recent Achievements and Near-term Strategic Priorities"},"content":{"rendered":"
\n

\n Burixafor (GPC-100) Phase 2 Trial in Multiple Myeloma Nears Key Readout<\/em>\n <\/p>\n

\n Preparing for Expansion into Sickle Cell Disease and Acute Myeloid Leukemia<\/em>\n <\/p>\n

\n New Leadership Appointments Bring Deep Drug Development Expertise<\/em>\n <\/p>\n

REDWOOD CITY, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) — Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today shared recent progress for its lead program, burixafor (GPC-100), outlined upcoming strategic priorities, and introduced new members of its leadership team who will help drive the company\u2019s next phase of growth.<\/p>\n

\u201cThe progress we\u2019ve achieved since integrating GPCR Therapeutics earlier this year reflects both the strength and potential of the burixafor program and the dedication of our team,\u201d said Andy Yoo, Chief Executive Officer of Exicure. \u201cAs we look ahead to our upcoming Phase 2 data readout and plan for expansion into new indications, I am energized by the opportunity to advance a program that could transform treatment approaches across multiple diseases.\u201d<\/p>\n

\n Burixafor Phase 2 Trial in Multiple Myeloma Nears Key Clinical Readout<\/strong>\n <\/p>\n

Exicure\u2019s ongoing Phase 2 study (NCT05561751) is a randomized, open-label, multicenter trial evaluating burixafor, a small molecule CXCR4 antagonist, in autologous stem cell transplant (ASCT) for multiple myeloma. By blocking CXCR4, burixafor is designed to mobilize hematopoietic stem cells out of the bone marrow and into the bloodstream, where they can be collected for use in transplant procedures.<\/p>\n

Interim results to date have been highly encouraging, with 100% of patients (10\/10) achieving the primary endpoint of successful CD34+ stem cell mobilization, including patients previously treated with daratumumab. Burixafor has a faster kinetics of mobilization with a well-tolerated safety profile, enabling same-day administration of the mobilizing agent and leukapheresis. This differentiates burixafor from FDA-approved agents such as plerixafor and motixafortide, which require overnight pre-treatment.<\/p>\n

In August, the company announced that the final patient had completed their last study visit. The clinical database has since been locked, and Exicure remains on track to report topline data in Q4 2025. Preparations are also underway for a potential Phase 3 trial.<\/p>\n

A full data publication from the ongoing Phase 2 trial (NCT05561751) is anticipated in 2026. In addition, a publication from a previous Phase 2 study (NCT02104427) evaluating burixafor in combination with G-CSF in patients with multiple myeloma, non-Hodgkin lymphoma, and Hodgkin disease, is currently under peer review.<\/p>\n

\n Expanding Development Opportunities<\/strong>\n <\/p>\n

Building on progress in multiple myeloma, Exicure is preparing to expand burixafor into additional indications:<\/p>\n